Private company

Kuvatris Therapeutics, Inc.

American pharmaceutical preparations company based in Tarrytown1

In its 2024 annual report the company says: “We are a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder, to neurodegenerative disorders such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, which causes physical and cognitive decline in affected adults.”3

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersTarrytown, New York1
  • Incorporated inDE2
  • Business address303 South Broadway, Suite 125, Tarrytown, Ny 105912
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (“ASD”), to neurodegenerative disorders such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), which causes physical and cognitive decline in affected adults. APTs have been shown to block the effects of excess production and extracellular receptor activity of adenosine triphosphate (“ATP”), which acts as both the main energy molecule in all living cells and a peripheral and central nervous system neurotransmitter via receptors that are found throughout the nervous system. Excess purinergic signaling can offset homeostasis and trigger immune responses tha…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-540.3%Return on equity4

Financial statements

Revenue54$0 in 2023
02022: $0$020222023: $0$02023
Operating income54-$16.1M in 2023+124% since 2021
-$20.0M-$15.0M-$10.0M-$5.0M02021: -$7.2M-$7.2M20212022: -$10.6M-$10.6M2022+47%2023: -$16.1M-$16.1M2023+52%
Net income54-$18.3M in 2023+79% since 2021
-$20.0M-$15.0M-$10.0M-$5.0M02021: -$10.2M-$10.2M20212022: -$14.8M-$14.8M2022+45%2023: -$18.3M-$18.3M2023+24%
Fiscal year2020202120222023
Revenue$05$04
Research and development$2.2M5$1.8M4$3.9M4
Operating expenses$7.2M5$10.6M4$16.1M4
Operating income-$7.2M5-$10.6M4-$16.1M4
Interest$2.8M5$5.2K4$9.2K4
Income before tax-$14.8M4-$18.3M4
Income tax$04$04
Net income-$10.2M5-$14.8M4-$18.3M4
Earnings per share-$1.535-$28.794-$11.004
Earnings per share (diluted)-$1.535-$28.794-$11.004
Shares (weighted, basic)6.7M shares5514.2K shares41.7M shares4
Shares (weighted, diluted)6.7M shares5514.2K shares41.7M shares4

Compare Kuvatris Therapeutics, Inc. with another company

Corporate structure

Kuvatris Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Kuvatris Therapeutics, Inc.

  • Lind Global Fund II LP Filed SCHEDULE 13G/A on Kuvatris Therapeutics, Inc., latest Feb 14, 2025 (4 filings since Nov 29, 2023)
  • Blue Cane Partners, LLC Filed SC 13G on Kuvatris Therapeutics, Inc., latest Sep 9, 2022
  • TardiMed Sciences LLC Filed SC 13D on Kuvatris Therapeutics, Inc., latest Sep 9, 2022
  • Kuvatris Therapeutics, Inc. Tarrytown, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Kuvatris Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Howard J. Weisman2022–2024

Chair

  1. Michael Derby2022–2023
  2. Howard J. Weisman2023

Chief financial officer

  1. Stephen Sheldon2022–2024

Chief operating officer

  1. Zachary Rome2022–2023
  2. Stephen Sheldon2023–2024
2025
Board members and other officers (6)

Former names

  • PaxMedica, Inc.May 15, 2020 to Jun 13, 20252

Timeline

  1. Jun 13, 20258-K Bylaws or fiscal year changed; Other events19
  2. Apr 4, 20258-K Executive or director change20
  3. Mar 7, 20258-K Entered a material agreement; Unregistered sale of shares; Change in control21
  4. Feb 6, 20258-K Executive or director change22
  5. Sep 6, 20248-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights23
  6. Jul 19, 20248-K Executive or director change24
  7. Jun 14, 20248-K Listing notice or transfer25
  8. May 28, 20248-K Shareholder vote26
  9. May 15, 20248-K Other events27
  10. May 1, 20248-K Listing notice or transfer28
  11. Apr 23, 20248-K Other events29
  12. Apr 16, 20248-K Other events30
  13. Aug 12, 2022New chief executive Howard J. Weisman becomes CEO9

Calendar

When it reported results

  1. Nov 16, 2023Reported quarterly or annual results31
  2. Nov 9, 2023Reported quarterly or annual results32
  3. Aug 9, 2023Reported quarterly or annual results33
  4. May 15, 2023Reported quarterly or annual results34
  5. Mar 30, 2023Reported quarterly or annual results35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

218 filings to the SEC since October 2021: 2 annual reports, 8 quarterly reports, 49 major events, 84 insider forms, 6 large holders, 1 private raises, 68 other. The latest 20:

  1. Jan 14, 202610-Q EDGAR
  2. Jun 13, 202515-12G EDGAR
  3. Jun 13, 20258-K EDGAR
  4. Apr 4, 20258-K EDGAR
  5. Mar 7, 20258-K EDGAR
  6. Feb 14, 2025SCHEDULE 13G/A EDGAR
  7. Feb 6, 20258-K EDGAR
  8. Nov 14, 2024NT 10-Q EDGAR
  9. Nov 14, 2024SC 13G/A EDGAR
  10. Oct 15, 2024EFFECT EDGAR
  11. Oct 10, 2024CORRESP EDGAR
  12. Oct 9, 2024UPLOAD EDGAR
  13. Oct 3, 2024S-1 EDGAR
  14. Sep 20, 202410-Q EDGAR
  15. Sep 6, 20248-K EDGAR
  16. Aug 14, 2024NT 10-Q EDGAR
  17. Jul 19, 20248-K EDGAR
  18. Jun 14, 20248-K EDGAR
  19. May 28, 20248-K EDGAR
  20. May 15, 20248-K EDGAR

The 218 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

52 open-market trades by officers, directors and large owners since October 2021: 2 buys and 50 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jan 29, 2024Rome ZacharyDirectorSale811$0.48$389Form 4
Jan 29, 2024LaRochelle KarenDirectorSale78$0.48$37Form 4
Jan 29, 2024Coelho John FDirectorSale27$0.48$13Form 4
Jan 29, 2024Weisman Howard J.Chief Executive OfficerSale372$0.47$175Form 4
Nov 27, 2023Coelho John FDirectorSale12$1.03$12Form 4
Nov 27, 2023Weisman Howard J.Chief Executive OfficerSale162$1.03$167Form 4
Nov 27, 2023Derby Michael10% ownerSale185$1.03$191Form 4
Nov 27, 2023LaRochelle KarenDirectorSale35$1.03$36Form 4
Nov 27, 2023Rome ZacharyDirectorSale359$1.03$370Form 4
Oct 27, 2023Rome ZacharyDirectorSale16,301$0.18$2.9KForm 4
Oct 27, 2023Derby Michael10% ownerSale9,175$0.19$1.7KForm 4
Oct 27, 2023Coelho John FDirectorSale570$0.19$108Form 4
Oct 27, 2023LaRochelle KarenDirectorSale1,679$0.19$319Form 4
Oct 27, 2023Weisman Howard J.Chief Executive OfficerSale8,049$0.19$1.5KForm 4
Aug 30, 2023Weisman Howard J.Chief Executive OfficerSale22,535$0.45$10.1KForm 4
Aug 30, 2023Rome ZacharyDirectorSale4,801$0.47$2.3KForm 4
Aug 29, 2023Coelho John FDirectorSale23$0.49$11Form 4
Aug 29, 2023Weisman Howard J.Chief Executive OfficerSale9,596$0.48$4.6KForm 4
Aug 29, 2023LaRochelle KarenDirectorSale456$0.48$219Form 4
Aug 29, 2023Rome ZacharyDirectorSale8,792$0.48$4.2KForm 4

All 52 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 25, 2022Raised $1.1 million in a private offering of debt Form D: $3.7 million offered in all Form D

SEC filer profile

How Kuvatris Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARKuvatris Therapeutics, Inc.1
  • CIK0001811623
  • Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address303 South Broadway, Suite 125, Tarrytown, NY 105911
  • Phone914-987-28761
  • Shares outstanding126,264,370 as of Jan 13, 20268
  • On EDGAR sinceMay 15, 20201
  • Filings239 in all: 4 (67), 8-K (49), CORRESP (15), S-1/A (12), UPLOAD (12), 3 (9), 10-Q (8), 3/A (6)1
    All 35 form types

    424B3 (6), EFFECT (6), S-1 (5), 144 (4), NT 10-Q (4), DEF 14A (3), PRE 14A (3), 10-K (2), 4/A (2), 424B4 (2), ARS (2), D (2), DRS (2), S-8 (2), SC 13G (2), SC 13G/A (2), SEC STAFF LETTER (2), 15-12G (1), 25-NSE (1), 8-A12B (1), CERT (1), DEFR14A (1), DRSLTR (1), FWP (1), POS AM (1), SC 13D (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 11, 2024
    Quarterly report (10-Q) Jan 14, 2026
    Proxy statement (DEF 14A) Apr 15, 2024
    Latest 8-K (8-K) Jun 13, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
    SEC EDGAROther events
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38